Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMT Stock Forecast 2026-2027
$7.35
Current Price
$453.88M
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SGMT Price Targets
+566.7%
To High Target of $49.00
+267.3%
To Median Target of $27.00
+8.8%
To Low Target of $8.00
SGMT Price Momentum
-3.4%
1 Week Change
+13.1%
1 Month Change
-25.8%
1 Year Change
+24.2%
Year-to-Date Change
-35.6%
From 52W High of $11.41
+63.3%
From 52W Low of $4.50
📊 TOP ANALYST CALLS
Did SGMT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sagimet is one of their latest high-conviction picks.
Latest SGMT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, SGMT has a bullish consensus with a median price target of $27.00 (ranging from $8.00 to $49.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $7.35, the median forecast implies a 267.3% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMT Analyst Ratings
8
Buy
1
Hold
0
Sell
SGMT Price Target Range
Low
$8.00
Average
$27.00
High
$49.00
Current: $7.35
Latest SGMT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2026 | Citizens | Jonathan Wolleben | Market Outperform | Maintains | $12.00 |
| May 4, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Apr 29, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Mar 11, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 3, 2026 | Guggenheim | Buy | Initiates | $N/A | |
| Feb 3, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 28, 2026 | Barclays | Equal-Weight | Initiates | $N/A | |
| Nov 14, 2025 | Citizens | Market Outperform | Maintains | $N/A | |
| Oct 22, 2025 | Clear Street | Buy | Initiates | $N/A | |
| Oct 2, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 11, 2025 | Wedbush | Outperform | Initiates | $N/A | |
| Aug 7, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $29.00 |
| Jul 24, 2025 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Jun 6, 2025 | Jones Trading | Buy | Maintains | $N/A | |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 27, 2025 | Jones Trading | Buy | Initiates | $N/A | |
| Dec 6, 2024 | Oppenheimer | Outperform | Initiates | $N/A | |
| Nov 15, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 12, 2024 | UBS | Buy | Initiates | $N/A |
Sagimet Biosciences Inc. (SGMT) Competitors
The following stocks are similar to Sagimet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sagimet Biosciences Inc. (SGMT) Financial Data
Sagimet Biosciences Inc. has a market capitalization of $453.88M with a P/E ratio of -4.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -36.0%.
Valuation Metrics
Market Cap
$453.88M
Enterprise Value
$349.38M
P/E Ratio
-4.7x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+23.0%
Current Ratio
20.3x
Debt/Equity
0.0x
ROE
-36.0%
ROA
-24.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sagimet Biosciences Inc. (SGMT) Business Model
About Sagimet Biosciences Inc.
What They Do
Develops therapeutics for fibrotic diseases and cancer.
Business Model
Sagimet Biosciences utilizes its proprietary platform to discover and develop small molecule drugs that modulate biological receptors involved in disease progression. The company primarily generates revenue through the development of its drug pipeline, which targets critical metabolic pathways in diseases such as nonalcoholic steatohepatitis (NASH) and various cancers.
Additional Information
With a focus on precision medicine and first-in-class therapeutics, Sagimet is positioned as a key player in novel drug discovery within the pharmaceutical industry, addressing significant unmet medical needs and aiming to improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Mr. David A. Happel
Country
United States
IPO Year
2023
Website
www.sagimet.comSagimet Biosciences Inc. (SGMT) Latest News & Analysis
Latest News
Quick Summary
Sagimet Biosciences Inc. (Nasdaq: SGMT) has been added to the Russell 3000® and Russell 2000® Indexes, effective today, as part of the 2026 Russell Indexes reconstitution.
Why It Matters
Sagimet Biosciences' inclusion in the Russell 3000 and Russell 2000 indexes may increase visibility and demand for its shares, potentially driving up stock price and attracting institutional investors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences (Nasdaq: SGMT) will engage in 1x1 investor meetings at the Leerink Partners Therapeutics Forum in Boston on July 15, 2026, focusing on its metabolic and fibrotic therapeutics.
Why It Matters
Sagimet Biosciences' participation in investor meetings signals potential interest and engagement with investors, which can influence stock performance and market perception of the company's future prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences Inc. (SGMT) has formed a hammer chart pattern, suggesting support. This, along with rising earnings estimates, may indicate a potential trend reversal.
Why It Matters
The hammer chart pattern signals potential price recovery for Sagimet Biosciences, while rising earnings estimates may attract buyers, suggesting a possible upward trend ahead.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
1 month ago
Quick Summary
Sagimet Biosciences presented Phase 1 clinical data demonstrating the safety and cholesterol-lowering effects of denifanstat and resmetirom at the EASL Congress 2026.
Why It Matters
Positive Phase 1 data on denifanstat and resmetirom indicate potential cardiovascular benefits, enhancing Sagimet's value and attractiveness to investors in the biopharmaceutical sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
1 month ago
Quick Summary
Analysts' price targets for Sagimet Biosciences (SGMT) suggest a 298.5% upside, supported by strong agreement in raised earnings estimates.
Why It Matters
Analysts' high price target suggests significant potential gains for Sagimet Biosciences, indicating bullish sentiment and possible positive momentum in the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
1 month ago
Quick Summary
Sagimet Biosciences secured $175M in equity financing. It plans a Phase 3 trial for denifanstat in acne in H2 2026 and expects funding to last through 2028, covering ongoing operations.
Why It Matters
Sagimet's successful equity financing and strong cash position signal financial stability, supporting ongoing clinical trials, which could lead to future product approvals and revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SGMT Stock
What is Sagimet Biosciences Inc.'s (SGMT) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Sagimet Biosciences Inc. (SGMT) has a median price target of $27.00. The highest price target is $49.00 and the lowest is $8.00.
Is SGMT stock a good investment in 2027?
According to current analyst ratings, SGMT has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMT stock?
Wall Street analysts predict SGMT stock could reach $27.00 in the next 12 months. This represents a 267.3% increase from the current price of $7.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sagimet Biosciences Inc.'s business model?
Sagimet Biosciences utilizes its proprietary platform to discover and develop small molecule drugs that modulate biological receptors involved in disease progression. The company primarily generates revenue through the development of its drug pipeline, which targets critical metabolic pathways in diseases such as nonalcoholic steatohepatitis (NASH) and various cancers.
What is the highest forecasted price for SGMT Sagimet Biosciences Inc.?
The highest price target for SGMT is $49.00 from at , which represents a 566.7% increase from the current price of $7.35.
What is the lowest forecasted price for SGMT Sagimet Biosciences Inc.?
The lowest price target for SGMT is $8.00 from at , which represents a 8.8% increase from the current price of $7.35.
What is the overall SGMT consensus from analysts for Sagimet Biosciences Inc.?
The overall analyst consensus for SGMT is bullish. Out of 3 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are SGMT stock price projections?
Stock price projections, including those for Sagimet Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 10, 2026 3:50 AM UTC